Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Name: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Published: 2022
License: Public Domain

AbbVie · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

cancer

chronic lymphocytic leukemia (cll), venetoclax, abt-199, venclexta, gdc-0199, obinutuzumab, gazyva, ga101, cancer, reveng, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)

Related documents